M. Pérol

18.9k total citations · 3 hit papers
292 papers, 7.0k citations indexed

About

M. Pérol is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, M. Pérol has authored 292 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 246 papers in Pulmonary and Respiratory Medicine, 205 papers in Oncology and 33 papers in Molecular Biology. Recurrent topics in M. Pérol's work include Lung Cancer Treatments and Mutations (211 papers), Lung Cancer Research Studies (100 papers) and Lung Cancer Diagnosis and Treatment (86 papers). M. Pérol is often cited by papers focused on Lung Cancer Treatments and Mutations (211 papers), Lung Cancer Research Studies (100 papers) and Lung Cancer Diagnosis and Treatment (86 papers). M. Pérol collaborates with scholars based in France, United States and Spain. M. Pérol's co-authors include Solange Peters, Rafael Rosell, Tony Mok, Shirish M. Gadgeel, D. Ross Camidge, Rafał Dziadziuszko, Jin Seok Ahn, Johannes Noé, Alice T. Shaw and Sai‐Hong Ignatius Ou and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

M. Pérol

268 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

2017 1.6k citations Solange Peters, D. Ross Camidge et al. profile →
Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

2020 414 citations D. Ross Camidge, Shirish M. Gadgeel et al. Annals of Oncology profile →
Oncogenic alterations in advanced NSCLC: a molecular super-highway

2024 47 citations M. Pérol et al. profile →

Peers

Countries citing papers authored by M. Pérol

Since Specialization

Citations

This map shows the geographic impact of M. Pérol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Pérol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Pérol more than expected).

Fields of papers citing papers by M. Pérol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Pérol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Pérol. The network helps show where M. Pérol may publish in the future.

Co-authorship network of co-authors of M. Pérol

This figure shows the co-authorship network connecting the top 25 collaborators of M. Pérol. A scholar is included among the top collaborators of M. Pérol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Pérol. M. Pérol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	175TiP: ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC 2025 ·Journal of Thoracic Oncology ·(unknown), (unknown), Paul E. Van Schil, (unknown), (unknown), (unknown), M. Pérol, (unknown), Kersti Oselin, (unknown), Heidi Roschitzki‐Voser, Eva Grolimund, Barbara Ruepp, Urania Dafni, (unknown), Solange Peters	1
2	Unresectable stage III non-small-cell lung cancer: state of the art and challenges 2025 ·Nature Reviews Clinical Oncology ·Jordi Remón, Antonin Lévy, (unknown), (unknown), (unknown), Lizza Hendriks, Corinne Faivre‐Finn, Natasha B. Leighl, Martin Reck, M. Pérol	0
3	Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST 2025 ·Journal of Clinical Oncology ·M. Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu, Yuichiro Ohe, Filippo de Braud, Misako Nagasaka, Enriqueta Felip, Anwen Xiong, Yongchang Zhang, Huijie Fan, Xicheng Wang, Shuanglian Li, Rose Lai, (unknown), Xianyu Zhang, Wenfeng Chen, Lyudmila Bazhenova, Caicun Zhou	10
4	1289P Pooled efficacy and safety from 2 pivotal phase II trials of taletrectinib in patients (Pts) with advanced or metastatic ROS1+ non-small cell lung cancer (NSCLC) 2024 ·Annals of Oncology ·M. Pérol, Wei Li, Nathan A. Pennell, Guimei Liu, (unknown), Filippo de Braud, Misako Nagasaka, Enriqueta Felip, (unknown), (unknown), Hongying Fan, Xu Wang, Bin Yan, (unknown), (unknown), Lyudmila Bazhenova, (unknown)	3
5	P1.12B.10 Dose Adjustments and Exposure-Response Associated with Selpercatinib in Patients with Advanced NSCLC 2024 ·Journal of Thoracic Oncology ·K. Park, Edurne Arriola, M. Pérol, C.Z. Zhou, (unknown), (unknown), Scott Barker, Ashish C. Massey, Patrick Peterson, (unknown), Ayman Akil, (unknown)	1
6	Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study. 2024 ·Journal of Clinical Oncology ·M. Pérol, Kōichi Goto, Benjamin Solomon, Keunchil Park, Ernest Nadal, Emilio Bria, (unknown), Jair Bar, (unknown), Tarun Puri, Li J, (unknown), Boris K. Lin, Caicun Zhou	0
7	IDeate-Lung02: A phase 3, randomized, open-label study of ifinatamab deruxtecan (I-DXd) vs treatment of physician’s choice (TPC) in relapsed small cell lung cancer (SCLC). 2024 ·Journal of Clinical Oncology ·Taofeek K. Owonikoko, Lauren A. Byers, Ying Cheng, Hidetoshi Hayashi, Luis Paz‐Ares, M. Pérol, Jennifer Turner, Meng Qian, (unknown), (unknown), Charles M. Rudin	8
8	Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. 2024 ·Journal of Clinical Oncology ·Pasi A. Jänne, (unknown), Toshio Kubo, Kiichiro Ninomiya, Sang‐We Kim, David Planchard, Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, Elvire Pons‐Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong‐Wan Kim, Kaline Pereira, (unknown), Ayumi Taguchi, Yingkai Cheng, Kōichi Goto	4
9	Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant (adj) osimertinib in patients (pts) with resected EGFR-mutated (EGFRm) stage IB–IIIA non-small cell lung cancer (NSCLC). 2024 ·Journal of Clinical Oncology ·Thomas John, Christian Grohé, Jonathan W. Goldman, Terufumi Kato, К. К. Лактионов, Laura Bonanno, Marcello Tiseo, Margarita Majem, Manuel Dómine, Myung‐Ju Ahn, M. Pérol, Ryan J. Hartmaier, Jacqulyne Robichaux, Preetida J. Bhetariya, Aleksandra Markovets, Yuri Rukazenkov, (unknown), Roy S. Herbst, Masahiro Tsuboi, Yi‐Long Wu	15
10	CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer 2024 ·Journal of Clinical Oncology ·M. Pérol, Benjamin Solomon, Kōichi Goto, Keunchil Park, Ernest Nadal, Emilio Bria, Claudio Martín, Jair Bar, (unknown), Tarun Puri, Li J, Minji K. Uh, Boris K. Lin, Caicun Zhou	5
11	Treatment patterns and clinical outcomes of extensive stage small cell lung cancer (SCLC) in the real-world evidence ESME cohort before the era of immunotherapy 2023 ·Respiratory Medicine and Research ·Clarisse Audigier-Valette, Thomas Filleron, D. Debieuvre, H. Léna, M. Pérol, C. Chouaïd, (unknown), Xavier Quantin, Nicolas Girard	5
12	Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. 2023 ·Journal of Clinical Oncology ·James Chih‐Hsin Yang, (unknown), Jong Seok Lee, Yun Fan, Filippo de Marinis, Isamu Okamoto, Takako Inoue, (unknown), Zhang Li, Cheng‐Ta Yang, Emmanuel de la Mora Jimenez, Jianying Zhou, M. Pérol, Ki Hyeong Lee, David Vicente, Eiki Ichihara, Gregory J. Riely, Yiwen Luo, Niyati Bhagwati, Shun Lü	50
13	Radiomics combined with transcriptomics to predict response to immunotherapy from patients treated with PD-1/PD-L1 inhibitors for advanced NSCLC 2023 ·SHILAP Revista de lepidopterología ·Amine Bouhamama, Benjamin Leporq, (unknown), Jean‐Philippe Foy, (unknown), M. Pérol, Sandra Ortiz‐Cuaran, François Ghiringhelli, Pierre Saintigny, Olivier Beuf, F. Pilleul	5
14	MA13.10 Trastuzumab Deruxtecan in Patients with HER2-Mutant Metastatic Non-Small Cell Lung Cancer: Primary Results of DESTINY-Lung02 2023 ·Journal of Thoracic Oncology ·Pasi A. Jänne, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, (unknown), (unknown), Myung‐Ju Ahn, Egbert F. Smit, Adrianus J. de Langen, M. Pérol, (unknown), Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, D.-W. Kim, (unknown), Fang Cheng, Ayumi Taguchi, Yun Cheng, Kōichi Goto	2
15	LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC 2023 ·Annals of Oncology ·(unknown), Keiko Goto, Benjamin Solomon, K. Park, M. Pérol, Edurne Arriola, Silvia Novello, Ying Cheng, Andrea Ardizzoni, Milena Perez Mak, Fernando C. Santini, Yasir Y. Elamin, (unknown), J. Wolf, (unknown), Hui Han, (unknown), Tarun Puri, Ilaria Vetrani, (unknown)	4
16	Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study 2022 ·Cancers ·R. Descourt, M. Pérol, (unknown), David Planchard, B. Mennecier, Marie Wislez, Jacques Cadranel, Alexis B. Cortot, Florian Guisier, Loïck Galland, Pascal Dô, Roland Schött, Éric Dansin, Jennifer Arrondeau, J.B. Auliac, Margaux Geier, C. Chouaïd	5
17	Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor–naive ALK + non−small cell lung cancer (ALTA-1L) 2021 ·Lung Cancer ·M.R. García Campelo, Huamao Mark Lin, Yanyan Zhu, M. Pérol, Mohammad Jahanzeb, Sanjay Popat, Pingkuan Zhang, D. Ross Camidge	12
18	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer 2021 ·Lung Cancer ·Sanjay Popat, Odd Terje Brustugun, J. Cadranel, Enriqueta Felip, Marina Chiara Garassino, Frank Griesinger, Åslaug Helland, Maximilian J. Hochmair, M. Pérol, (unknown), (unknown), Silvia Novello	13
19	Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology 2017 ·Clinical Lung Cancer ·Cesare Gridelli, Paul Baas, Fabrice Barlési, Fortunato Ciardiello, Lucio Crinò, Enriqueta Felip, Shirish M. Gadgeel, Vali Papadimitrakopoulou, Luis Paz‐Ares, David Planchard, M. Pérol, Nasser H. Hanna, Assunta Sgambato, Francesca Casaluce, Filippo de Marinis	8
20	Randomized, Phase III Study of Gemcitabine or Erlotinib Maintenance Therapy Versus Observation, With Predefined Second-Line Treatment, After Cisplatin-Gemcitabine Induction Chemotherapy in Advanced Non–Small-Cell Lung Cancer 2012 ·Journal of Clinical Oncology ·M. Pérol, C. Chouaïd, David Pérol, Fabrice Barlési, Radj Gervais, Virginie Westeel, Jacky Créquit, H. Léna, A. Vergnenègre, Gérard Zalcman, I. Monnet, H. Le Caer, P. Fournel, L. Falchero, M. Poudenx, F. Vaylet, Céline Ségura‐Ferlay, Mojgan Devouassoux‐Shisheboran, Miquel Tarón, B. Milleron	166

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact